Literature DB >> 26560494

Prospects for the future of prostate cancer vaccines.

Ravi A Madan1, James L Gulley1.   

Abstract

Cancer therapy is undergoing a revolution fueled by clinical data demonstrating that the immune system has significant anti-tumor capability. Although the main focus of this revolution currently rests upon immune checkpoint inhibitors in diseases such as melanoma, lung and bladder cancer, it was actually a therapeutic cancer vaccine in prostate cancer that provided the first data demonstrating that a modern immunotherapy, beyond cytokines, could enhance clinical outcomes. As immunotherapy is poised to take center stage among cancer therapies, the role of cancer vaccines remains somewhat undefined in prostate cancer, though emerging data suggest that vaccines could play a crucial therapeutic role.

Entities:  

Keywords:  Vaccines; combination therapy; immune combinations; prostate cancer; therapeutic cancer vaccines

Mesh:

Substances:

Year:  2015        PMID: 26560494      PMCID: PMC6641856          DOI: 10.1586/14760584.2015.1118348

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  4 in total

Review 1.  Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?

Authors:  Andrew L Laccetti; Sumit K Subudhi
Journal:  Curr Opin Urol       Date:  2017-11       Impact factor: 2.309

Review 2.  Developing immunotherapy strategies in the treatment of prostate cancer.

Authors:  James L Gulley; Ravi A Madan
Journal:  Asian J Urol       Date:  2016-08-30

Review 3.  Emerging therapeutic agents for genitourinary cancers.

Authors:  Kevin Zarrabi; Azzam Paroya; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

4.  Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.

Authors:  Xin Rui; Siliang Shao; Li Wang; Jiangyong Leng
Journal:  BMC Cancer       Date:  2019-12-03       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.